0001209191-22-035081.txt : 20220608 0001209191-22-035081.hdr.sgml : 20220608 20220608170108 ACCESSION NUMBER: 0001209191-22-035081 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220607 FILED AS OF DATE: 20220608 DATE AS OF CHANGE: 20220608 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Simson Jake CENTRAL INDEX KEY: 0001863094 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40794 FILM NUMBER: 221004102 MAIL ADDRESS: STREET 1: C/O JANUX THERAPEUTICS, INC. STREET 2: 11099 N. TORREY PINES ROAD, SUITE 290 CITY: LA JOLLA STATE: CA ZIP: 92037 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: DICE Therapeutics, Inc. CENTRAL INDEX KEY: 0001645569 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472286244 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 279 E. GRAND AVENUE, SUITE 300, LOBBY B CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-566-1402 MAIL ADDRESS: STREET 1: 279 E. GRAND AVENUE, SUITE 300, LOBBY B CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: DiCE MOLECULES HOLDINGS, LLC DATE OF NAME CHANGE: 20180725 FORMER COMPANY: FORMER CONFORMED NAME: DiCE Molecules Holdings, LLC DATE OF NAME CHANGE: 20150617 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-06-07 0 0001645569 DICE Therapeutics, Inc. DICE 0001863094 Simson Jake C/O DICE THERAPEUTICS, INC. 400 EAST JAMIE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 1 0 0 0 Stock Option (right to buy Common Stock) 14.98 2022-06-07 4 A 0 21250 0.00 A 2032-06-06 Common Stock 21250 21250 D The option vests on the earlier to occur of: (i) the one-year anniversary of the grant date and (ii) the subsequent annual meeting of the Registrant's stockholders, in each case, subject to the Reporting Holder's continued service to the Registrant. Under the Reporting Holder's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Holder holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and the RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The Reporting Holder is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund II. The Reporting Holder therefore disclaims beneficial ownership of the stock option and underlying Common Stock. /s/ Scott Robertson as attorney-in-fact for Jake Simson 2022-06-08